Crinetics Pharmaceuticals CRNX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -3,020.3%+46,549pp | -6,714.8%+25,899pp | -31,130.2%-1,605pp | -30,392.2%-10,324pp | -49,569.7%-36,998pp | |
| Net margin | -2,747.2%+40,444pp | -6,046.2%+22,674pp | -27,563.3%-815pp | -26,568.5%-7,901pp | -43,191.1%-31,263pp | |
| Returns | ||||||
| Return on equity | -39.2%-8.3pp | -40.2%-8.1pp | -44.4%-4.2pp | -36.9%+10.7pp | -30.8%+9.9pp | |
| Return on invested capital | -45.1%-1.8pp | -50.4%-9.3pp | -60.6%-0.7pp | -48.4%+21.2pp | -43.3%+20.9pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 18.6×-3.9× | 12.3×-10.7× | 15.1×-1.3× | 17.8×+1.7× | 22.5×+4.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $12.30-8.7% | $10.55-35.7% | $11.38+9.4% | $12.49+18.8% | $13.47+11.3% | |
| Valuation | ||||||
| Market capitalization | $3.8B+21.9% | $4.42B-6.8% | $3.92B-4.1% | $2.9B-17.9% | $3.12B-14.4% | |
| Price / sales | 210.5×-3,896× | 574×-3,990× | 2,555.3×-1,381× | 2,082.2×-468× | 4,106.4×+2,258× | |
| Price / book | 3×+0.5× | 4.5×+0.9× | 3.7×-1.3× | 2.5×-1.8× | 2.5×-1.7× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Crinetics Pharmaceuticals's profit margins?
- Crinetics Pharmaceuticals (CRNX) runs a 150.0% gross margin and a -3020.3% operating margin, with a -2747.2% net margin.
- Where do Crinetics Pharmaceuticals's ratios come from?
- Every ratio is computed from Crinetics Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
